HCW Biologics
HCWB
12 hedge funds and large institutions have $1.25M invested in HCW Biologics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 0 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
248% more capital inflows, than outflows
Capital inflows: $93.8K | Capital outflows: $27K
0.08% more ownership
Funds ownership: 1.51% → 1.59% (+0.08%)
0% more funds holding
Funds holding: 12 → 12 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
+$37.6K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$23.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1K |
| 4 |
BlackRock
New York
|
+$7.86K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$6.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$27K |
HCWB Hedge Fund Activity: Q2 2022 in Review
12 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q2 2022, worth a combined $1.25M — down 15% from $1.48M a quarter earlier.
Fund positioning in HCWB was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 8 added to existing stakes and 1 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $37.6K. The largest seller was Two Sigma Investments, cutting an estimated $27K.
- 12 institutional investors held HCW Biologics (HCWB) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.25M of HCW Biologics stock for Q2 2022, down 15% quarter-over-quarter.
- 0 funds opened new HCW Biologics positions in Q2 2022 and 0 closed out.
- The largest HCW Biologics buyer in Q2 2022 was Bridgeway Capital Management, an estimated $37.6K added.
- The largest HCW Biologics seller in Q2 2022 was Two Sigma Investments, an estimated $27K sold.
Based on aggregated 13F filings for Q2 2022.